ABSTRACT
Gene therapy is a rapidly developing field in which recombinant nucleic acid sequences are introduced to individuals. Its therapeutic, prophylactic or diagnostic effect relates directly to the sequence it contains or to the product of genetic expression of this sequence. Recombinant adenoviral vectors (in particular HAdV-5 vectors) are frequently used in gene therapy. Knowledge on biodistribution and shedding is crucial in the risk assessment for the patient and the patient's environment. This review presents a critical overview on biodistribution and shedding data of non-replicating viral vector HAdV-5, related to the used administration route. Based on these data, a qualitative model for the biodistribution and shedding of HAdV-5 based viral vectors is presented. Biodistribution and shedding depend on the route of administration. Some routes lead to local biodistribution and no shedding or one shedding route only. Other routes lead to systemic biodistribution and to shedding via several excreta. Shedding via semen and transport across the blood-brain barrier is not expected for HAdV-5. The presented qualitative model can help researchers and risk assessors to determine the possible distribution in the body and the risk of shedding via the different excretion routes. Furthermore, it can help regulators to predict the different shedding routes after a certain administration route and thus in deciding which studies are warranted or which safety precautions are needed after administration to patients.
Subject(s)
Adenoviridae/genetics , Genetic Therapy , Genetic Vectors , Virus Shedding , Animals , Clinical Trials as Topic , DNA, Recombinant/administration & dosage , DNA, Recombinant/pharmacokinetics , Drug Administration Routes , Genetic Vectors/administration & dosage , Genetic Vectors/pharmacokinetics , Humans , Models, Biological , Virus ReplicationABSTRACT
Gene therapy is a rapidly developing field in which recombinant nucleic acid sequences are introduced to individuals to regulate, repair, replace, add or delete a genetic sequence. Recombinant adeno-associated viral (AAV) vectors, especially AAV2, are frequently used in gene therapy. Knowledge on the biodistribution and potential shedding of AAV2 is crucial to evaluate the risks of infection with the viral vector for the patient and the environment. Literature was analysed for biodistribution and shedding data for AAV2. Preclinical and clinical studies were included with a focus on the influence of the administration route on spreading. Based on biodistribution and shedding data, a qualitative model for the biodistribution and shedding of AAV2 related to the administration route is presented. It is concluded that biodistribution and shedding of AAV2 depends on the route of administration. Some routes lead to local biodistribution and thus to no shedding or shedding via one route only. Other routes lead to systemic biodistribution and to shedding via several excretion routes. The qualitative model presented can help to determine the possible biodistribution in the body and the risk of shedding via the different excretion routes. In addition, it can help to predict the different shedding routes after a certain administration route of AAV2 and thus in deciding which studies are warranted or which safety precautions are needed after administration to patients.
Subject(s)
Dependovirus/genetics , Genetic Therapy , Genetic Vectors , Models, Biological , Virus Shedding , Animals , Clinical Trials as Topic , DNA, Recombinant/administration & dosage , DNA, Recombinant/pharmacokinetics , Drug Administration Routes , Genetic Vectors/administration & dosage , Genetic Vectors/pharmacokinetics , Humans , Virus ReplicationABSTRACT
Cell membranes can be transiently permeabilized under application of electric pulses that allow hydrophilic therapeutic molecules, such as anticancer drugs and DNA, to enter into cells and tissues. This process, called electropermeabilization or electroporation, has been rapidly developed over the last decade to deliver genes to tissues and organs, but there is a general agreement that very little is known about what is really occurring during membrane electropermeabilization. It is well accepted that the entry of small molecules, such as anticancer drugs, occurs through simple diffusion while the entry of macromolecules, such as DNA, occurs through a multistep mechanism involving the electrophoretically driven association of the DNA molecule with the destabilized membrane and then its passage across the membrane. Therefore, successful DNA electrotransfer into cells depends not only on cell permeabilization but also on the way plasmid DNA interacts with the plasma membrane and, once into the cell, migrates toward the nuclei.
Subject(s)
DNA, Recombinant/administration & dosage , Electrochemotherapy , Genetic Therapy , Animals , Biological Transport, Active , Cell Membrane Permeability , DNA, Recombinant/genetics , DNA, Recombinant/pharmacokinetics , Electrochemotherapy/methods , Electrophoresis , Electroporation/methods , Gene Expression , Gene Transfer Techniques , Genetic Therapy/methods , Humans , Membrane Potentials , Plasmids/administration & dosage , Plasmids/genetics , Plasmids/pharmacokineticsABSTRACT
A plasmid DNA that encodes chicken interleukin-2 (pCI-ChIL-2-EGFP) was investigated for its distribution and expression after intramuscular (i.m.) injection in chickens. After the i.m. injection, serum distribution was detectable from 2 h post inoculation (p.i.), peaked at 8 h p.i., and disappeared at 7 days p.i. The plasmid DNA was also observed in several organs including heart, liver, lung, spleen, bursa and inoculated muscle at different time points, but at 19 days p.i. the plasmid DNA was not found in any organ except inoculated muscle. Fluorescence of enhanced green fluorescent protein (EGFP) was found in cytoplasm and nucleus of cultured Vero cells, chicken embryo fibroblasts and peripheral blood lymphocytes, which were transfected in vitro with the plasmid DNA or in vivo with Lipofectamine. The expression profile of the fusion gene (ChIL-2-EGFP) in vivo was measured by RT-PCR, ELISA and fluorescence microscopy. The EGFP expression was detected from 8 h p.i. to 14 days p.i. and peaked at 5 days p.i., when the number of EGFP-expression myocytes was about 5% in the injected site. These results demonstrate that intramuscular administration of plasmid DNA leads to widespread distribution and long-term expression in vivo.
Subject(s)
Chickens/metabolism , DNA, Recombinant/administration & dosage , Interleukin-2/genetics , Plasmids/pharmacokinetics , Animals , Chick Embryo , Chickens/immunology , Chlorocebus aethiops , Cloning, Molecular , DNA, Recombinant/genetics , DNA, Recombinant/immunology , DNA, Recombinant/pharmacokinetics , Enzyme-Linked Immunosorbent Assay/veterinary , Interleukin-2/biosynthesis , Interleukin-2/blood , Interleukin-2/immunology , Microscopy, Fluorescence/veterinary , Plasmids/genetics , Plasmids/metabolism , Random Allocation , Recombinant Fusion Proteins/biosynthesis , Recombinant Fusion Proteins/genetics , Reverse Transcriptase Polymerase Chain Reaction/veterinary , Specific Pathogen-Free Organisms , Transfection/veterinary , Vero CellsABSTRACT
BACKGROUND: To investigate the nuclear import mechanism of plasmid/polyethylenimine (PEI) derivative complexes and the putative nuclear targeting of therapeutic genes by the use of oligosaccharides, we have studied the nuclear import of plasmid DNA complexed either with PEI or with lactosylated PEI (Lac-PEI) in cystic fibrosis human airway epithelial cells ( summation operatorCFTE29o- cells). METHODS AND RESULTS: Cells were synchronized by a double-thymidine block protocol and gene transfer efficiency was evaluated: Lac-PEI- and PEI-mediated gene transfer was greatly increased when cells have undergone mitosis during the course of transfection. However, both types of complexes were able to transfect some growth-arrested cells. When the nuclear import of plasmid/Lac-PEI or plasmid/unsubstituted PEI complexes was studied in digitonin-permeabilized cells, the nuclear uptake of both types of complexes did not follow the classic pathway of nuclear localization sequence (NLS)-containing proteins and lactose residues did not act as a nuclear localization signal. CONCLUSIONS: Our results show that for complexes made with PEI derivatives, the major route for plasmid DNA nuclear entry is a passive nuclear importation during mitosis when the nuclear membrane temporarily breaks down. However, albeit to a lesser extent as that observed in dividing cells, a plasmid DNA importation also occurs in nondividing cells by a yet unknown mechanism.
Subject(s)
DNA, Recombinant/pharmacokinetics , Gene Transfer Techniques , Plasmids/administration & dosage , Plasmids/pharmacokinetics , Active Transport, Cell Nucleus , Cell Cycle , Cell Line , DNA, Recombinant/administration & dosage , DNA, Recombinant/chemistry , DNA, Recombinant/genetics , Green Fluorescent Proteins/genetics , Humans , Macromolecular Substances , Microinjections , Mitosis , Plasmids/chemistry , Plasmids/genetics , Polyethyleneimine , Recombinant Proteins/geneticsABSTRACT
BACKGROUND: In previous studies, we showed that the immobilisation of DNAs encoding basic fibroblast growth factor, neurotrophin-3 and brain-derived neurotrophic factor in a gene-activated matrix (GAM) promotes sustained survival of axotomised retinal ganglion cells after optic nerve injury. Here, we evaluated if the immobilisation of DNAs in a GAM could be an effective approach to deliver genes to axotomised dorsal root ganglion (DRG) neurones after spinal cord injury and if the matrix component of the GAM would modulate the deposition of a dense scar at the injury site. METHODS: We evaluated the expression of the thymidine kinase (TK) reporter gene in brain cortex and DRG after a bilateral T8 dorsal column (DC) lesion using PCR, RT-PCR and in situ hybridisation analyses. Collagen-based GAMs were implanted at the lesion site and the cellular response to the GAM was assessed using cell-specific markers. RESULTS: At 1 week post-injury, PCR analyses confirmed that DNATK was retrogradely transported from the DC lesion where the GAM was implanted to the brain cortex and to caudal DRG neurones, and RT-PCR analyses showed expression of mRNATK. At 7 weeks post-injury, DNATK was still be detected in the GAM and DRG. In situ hybridisation localised DNATK and mRNATK within fibroblasts, glia, endothelial and inflammatory cells invading the GAM and in DRG neurones. Interestingly, the presence of a GAM also reduced secondary cavitation and scar deposition at the lesion site. CONCLUSIONS: These results establish that GAMs act as bridging scaffolds in DC lesions limiting cavitation and scarring and delivering genes both locally to injury-reactive cells and distally to the cerebral cortex and to DRG neuronal somata through retrograde axonal transport.
Subject(s)
Cerebral Cortex/metabolism , DNA, Recombinant/administration & dosage , DNA, Recombinant/pharmacokinetics , Ganglia, Spinal/metabolism , Gene Transfer Techniques , Spinal Cord Injuries/therapy , Animals , Axonal Transport , Female , Gene Expression , Genes, Reporter , In Situ Hybridization , Neurons/metabolism , Polymerase Chain Reaction , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats , Rats, Wistar , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Spinal Cord Injuries/genetics , Spinal Cord Injuries/metabolism , Spinal Cord Injuries/pathology , Thymidine Kinase/genetics , Thymidine Kinase/metabolismSubject(s)
Adenoviridae , Gene Transfer Techniques/trends , Genetic Vectors/pharmacokinetics , Adenoviridae/genetics , Adenoviridae/pathogenicity , Animals , DNA, Recombinant/pharmacokinetics , Genetic Therapy/trends , Genetic Vectors/therapeutic use , Humans , Membrane Cofactor Protein/metabolism , Oncolytic Virotherapy/trendsABSTRACT
The past several years have witnessed the evolution of gene medicine from an experimental technology into a viable strategy for developing therapeutics for a wide range of human disorders. Numerous prototype DNA-based biopharmaceuticals can now control disease progression by induction and/or inhibition of genes. These potent therapeutics include plasmids containing transgenes, oligonucleotides, aptamers, ribozymes, DNAzymes, and small interfering RNAs. Although only 2 DNA-based pharmaceuticals (an antisense oligonucleotide formulation, Vitravene, (USA, 1998), and an adenoviral gene therapy treatment, Gendicine (China, 2003), have received approval from regulatory agencies; numerous candidates are in advanced stages of human clinical trials. Selection of drugs on the basis of DNA sequence and structure has a reduced potential for toxicity, should result in fewer side effects, and therefore should eventually yield safer drugs than those currently available. These predictions are based on the high selectivity and specificity of such molecules for recognition of their molecular targets. However, poor cellular uptake and rapid in vivo degradation of DNA-based therapeutics necessitate the use of delivery systems to facilitate cellular internalization and preserve their activity. This review discusses the basis of structural design, mode of action, and applications of DNA-based therapeutics. The mechanisms of cellular uptake and intracellular trafficking of DNA-based therapeutics are examined, and the constraints these transport processes impose on the choice of delivery systems are summarized. Finally, the development of some of the most promising currently available DNA delivery platforms is discussed, and the merits and drawbacks of each approach are evaluated.
Subject(s)
DNA/therapeutic use , Genetic Therapy/methods , Antisense Elements (Genetics)/administration & dosage , Antisense Elements (Genetics)/pharmacokinetics , Antisense Elements (Genetics)/therapeutic use , Aptamers, Nucleotide/administration & dosage , Aptamers, Nucleotide/pharmacokinetics , Aptamers, Nucleotide/therapeutic use , Biological Transport , DNA/administration & dosage , DNA/genetics , DNA/pharmacokinetics , DNA, Catalytic/administration & dosage , DNA, Catalytic/pharmacokinetics , DNA, Catalytic/therapeutic use , DNA, Recombinant/administration & dosage , DNA, Recombinant/genetics , DNA, Recombinant/pharmacokinetics , DNA, Recombinant/therapeutic use , Dosage Forms , Drug Delivery Systems , Drug Design , Genes, Transgenic, Suicide , Genetic Vectors/administration & dosage , Genetic Vectors/pharmacokinetics , Genetic Vectors/therapeutic use , Humans , Liposomes/administration & dosage , Liposomes/classification , Plasmids/administration & dosage , Plasmids/genetics , Plasmids/therapeutic use , RNA, Catalytic/administration & dosage , RNA, Catalytic/pharmacokinetics , RNA, Catalytic/therapeutic use , RNA, Small Interfering/administration & dosage , RNA, Small Interfering/pharmacokinetics , RNA, Small Interfering/therapeutic use , TransgenesABSTRACT
The administration of naked nucleic acids into animals is increasingly being used as a research tool to elucidate mechanisms of gene expression and the role of genes and their cognate proteins in the pathogenesis of disease in animal models (Herweijer and Wolff, 2003; Hodges and Scheule, 2003). It is also being used in several human clinical trials for genetic vaccines, Duchenne muscular dystrophy, peripheral limb ischemia, and cardiac ischemia (Davis et al., 1996; Romero et al., 2002; Tsurumi et al., 1997). Naked DNA is an attractive non-viral vector because of its inherent simplicity and because it can easily be produced in bacteria and manipulated using standard recombinant DNA techniques. It shows very little dissemination and transfection at distant sites following delivery and can be readministered multiple times into mammals (including primates) without inducing an antibody response against itself (i.e., no anti-DNA antibodies generated) (Jiao et al., 1992). Also, contrary to common belief, long-term foreign gene expression from naked plasmid DNA (pDNA) is possible even without chromosome integration if the target cell is postmitotic (as in muscle) or slowly mitotic (as in hepatocytes) and if an immune reaction against the foreign protein is not generated (Herweijer et al., 2001; Miao et al., 2000; Wolff et al., 1992; Zhang et al., 2004). With the advent of intravascular and electroporation techniques, its major restriction--poor expression levels--is no longer limiting and levels of foreign gene expression in vivo are approaching what can be achieved with viral vectors. Direct in vivo gene transfer with naked DNA was first demonstrated when efficient transfection of myofibers was observed following injection of mRNA or pDNA into skeletal muscle (Wolff et al., 1990). It was an unanticipated finding in that the use of naked nucleic acids was the control for experiments designed to assess the ability of cationic lipids to mediate expression in vivo. Subsequent studies also found foreign gene expression after direct injection in other tissues such as heart, thyroid, skin, and liver (Acsadi et al., 1991; Hengge et al., 1996; Kitsis and Leinwand, 1992; Li et al., 1997; Sikes and O'Malley 1994; Yang and Huang, 1996). However, the efficiency of gene transfer into skeletal muscle and these other tissues by direct injection is relatively low and variable, especially in larger animals such as nonhuman primates (Jiao et al., 1992). After our laboratory had developed novel transfection complexes of pDNA and amphipathic compounds and proteins, we sought to deliver them to hepatocytes in vivo via an intravascular route into the portal vein. Our control for these experiments was naked pDNA and we were once again surprised that this control group had the highest expression levels (Budker et al., 1996; Zhang et al., 1997). High levels of expression were achieved by the rapid injection of naked pDNA in relatively large volumes via the portal vein, the hepatic vein, and the bile duct in mice and rats. The procedure also proved effective in larger animals such as dogs and nonhuman primates (Eastman et al., 2002; Zhang et al., 1997). The next major advance was the demonstration that high levels of expression could also be achieved in hepatocytes in mice by the rapid injection of naked DNA in large volumes simply into the tail vein (Liu et al., 1999; Zhang et al., 1999). This hydrodynamic tail vein (HTV) procedure is proving to be a very useful research tool not only for gene expression studies, but also more recently for the delivery of small interfering RNA (siRNA) (Lewis et al., 2002; McCaffrey et al., 2002). The intravascular delivery of naked pDNA to muscle cells is also attractive particularly since many muscle groups would have to be targeted for intrinsic muscle disorders such as Duchenne muscular dystrophy. High levels of gene expression were first achieved by the rapid injection of naked DNA in large volumes via an artery route with both blood inflow and outflow blocked surgically (Budker et al., 1998; Zhang et al., 2001). Intravenous routes have also been shown to be effective (Hagstrom et al., 2004; Liang et al., 2004; Liu et al., 2001). For limb muscles, the ability to use a peripheral limb vein for injection and a proximal, external tourniquet to block blood flow renders the procedure to be clinically viable. This review concerns itself with the mechanism by which naked DNA is taken up by cells in vivo. A greater understanding of the mechanisms involved in the uptake and expression of naked DNA, and thus connections between postulated mechanisms and expression levels, is emphasized. Inquiries into the mechanism not only aid these practical efforts, but are also interesting on their own account with relevance to viral transduction and cellular processes. The delivery to hepatocytes is first discussed given the greater information available for this process, and then uptake by myofibers is discussed.
Subject(s)
DNA, Recombinant/genetics , DNA, Recombinant/pharmacokinetics , Active Transport, Cell Nucleus , Animals , Biological Transport, Active , Cytoplasm/metabolism , DNA, Recombinant/administration & dosage , Gene Expression , Hepatocytes/metabolism , Humans , Muscle Cells/metabolism , Plasmids/administration & dosage , Plasmids/genetics , Plasmids/pharmacokinetics , Vaccines, DNA/administration & dosage , Vaccines, DNA/genetics , Vaccines, DNA/pharmacokineticsABSTRACT
Given both the accessibility and the genetic basis of several pulmonary diseases, the lungs and airways initially seemed ideal candidates for gene therapy. Several routes of access are available, many of which have been refined and optimized for nongene drug delivery. Two respiratory diseases, cystic fibrosis (CF) and alpha1-antitrypsin (alpha1-AT) deficiency, are relatively common; the single gene responsible has been identified and current treatment strategies are not curative. This type of inherited disease was the obvious initial target for gene therapy, but it has become clear that nongenetic and acquired diseases, including cancer, may also be amenable to this approach. The majority of preclinical and clinical studies in the airway have involved viral vectors, although for diseases such as CF, likely to require repeated application, non-viral delivery systems have clear advantages. However, with both approaches a range of barriers to gene expression have been identified that are limiting success in the airway and alveolar region. This chapter reviews these issues, strategies aimed at overcoming them, and progress into clinical trials with non-viral vectors in a variety of pulmonary diseases.
Subject(s)
Genetic Therapy/methods , Respiratory Tract Diseases/therapy , Animals , Asthma/genetics , Asthma/therapy , Biological Transport, Active , Cystic Fibrosis/genetics , Cystic Fibrosis/therapy , DNA, Recombinant/administration & dosage , DNA, Recombinant/genetics , DNA, Recombinant/pharmacokinetics , Electroporation , Gene Expression , Gene Transfer Techniques , Genetic Therapy/adverse effects , Humans , Lung Injury , Lung Transplantation , Magnetics , Neoplasms/genetics , Neoplasms/therapy , Pulmonary Fibrosis/genetics , Pulmonary Fibrosis/therapy , Respiratory Tract Diseases/genetics , Ultrasonics , alpha 1-Antitrypsin Deficiency/genetics , alpha 1-Antitrypsin Deficiency/therapyABSTRACT
This study aimed to evaluate the possibility of DNA sequences from genetically modified plants to persist in the gastrointestinal (GI) tract. PCR analysis and transformation assays were used to study DNA persistence and integrity in various ex vivo and in vivo systems using gnotobiotic rats. DNA studied was either plasmid DNA, naked plant DNA or plant DNA embedded in maize flour. Ex vivo experiments performed by incubating plant DNA in intestinal samples, showed that DNA is rapidly degraded in the upper part of the GI tract whereas degradation is less severe in the lower part. In contrast, plasmid DNA could be recovered throughout the GI tract when intestinal samples were taken up to 5 h after feeding rats with plasmid. Furthermore, DNA isolated from these intestinal samples was able to transform electro-competent Escherichia coli, showing that the plasmid was still biologically active. The results indicate that ingested DNA may persist in the GI tract and consequently may be present for uptake by intestinal bacteria.
Subject(s)
DNA, Plant/pharmacokinetics , DNA, Recombinant/pharmacokinetics , Gastrointestinal Tract/metabolism , Plants, Genetically Modified , Animals , DNA Primers/chemistry , DNA, Plant/analysis , DNA, Recombinant/analysis , Electroporation , Gastrointestinal Contents/chemistry , Gastrointestinal Tract/chemistry , Genes, Plant , Germ-Free Life , Male , Plasmids/genetics , Polymerase Chain Reaction , Rats , Rats, Wistar , Solanum tuberosum/genetics , Transduction, Genetic , Zea mays/geneticsABSTRACT
Despite the popularity of adeno-associated virus 2 (AAV2) as a vehicle for gene transfer, its efficacy for liver-directed gene therapy in hemophilia A or B has been suboptimal. Here we evaluated AAV serotypes 2, 5, 7, and 8 in gene therapy of factor VIII (FVIII) deficiency in a hemophilia A mouse model and found that AAV8 was superior to the other 3 serotypes. We expressed canine B domain-deleted FVIII cDNA either in a single vector or in 2 separate AAV vectors containing the heavy- and light-chain cDNAs. We also evaluated AAV8 against AAV2 in intraportal and tail vein injections. AAV8 gave 100% correction of plasma FVIII activity irrespective of the vector type or route of administration.
Subject(s)
Adenoviridae/genetics , Factor VIII/genetics , Genetic Therapy/methods , Hemophilia A/therapy , Adenoviridae/classification , Animals , Blotting, Southern , DNA, Recombinant/pharmacokinetics , Dogs , Female , Genetic Vectors , Hemophilia A/genetics , Liver , Male , Mice , Mice, Mutant Strains , Portal Vein , Tail/blood supplyABSTRACT
The inclusion of genetically modified (GM) foods in the human diet has caused considerable debate. There is concern that the transfer of plant-derived transgenes to the resident intestinal microflora could have safety implications. For these gene transfer events to occur, the nucleic acid would need to survive passage through the gastrointestinal tract. The aim of the present study was to evaluate the rate at which transgenes, contained within GM soya and maize, are degraded in gastric and small bowel simulations. The data showed that 80 % of the transgene in naked GM soya DNA was degraded in the gastric simulations, while no degradation of the transgenes contained within GM soya and maize were observed in these acidic conditions. In the small intestinal simulations, transgenes in naked soya DNA were degraded at a similar rate to the material in the soya protein. After incubation for 30 min, the transgenes remaining in soya protein and naked DNA were 52 (sem 13.1) % and 34 (sem 17.5) %, respectively, and at the completion of the experiment (3 h) these values were 5 % and 3 %, respectively. In contrast to the soya transgene, the maize nucleic acid was hydrolysed in the small intestinal simulations in a biphasic process in which approximately 85 % was rapidly degraded, while the rest of the DNA was cleaved at a rate similar to that in the soya material. Guar gum and tannic acid, molecules that are known to inhibit digestive enzymes, did not influence the rate of transgene degradation in soya protein. In contrast guar gum reduced the rate of transgene degradation in naked soya DNA in the initial stages, but the polysaccharide did not influence the amount of nucleic acid remaining at the end of the experiment. Tannic acid reduced the rate of DNA degradation throughout the small bowel simulations, with 21 (sem 5.4) % and 2 (sem 1.8) % of the naked soya DNA remaining in the presence and absence of the phenolic acid, respectively. These data indicate that some transgenes in GM foods may survive passage through the small intestine.
Subject(s)
DNA, Plant/pharmacokinetics , Glycine max/genetics , Intestine, Small/metabolism , Plants, Genetically Modified , Transgenes , Zea mays/genetics , DNA, Recombinant/pharmacokinetics , Galactans/pharmacology , Gastric Mucosa/metabolism , Gastrointestinal Contents , Genes, Plant , Humans , Hydrochloric Acid/pharmacology , Hydrolyzable Tannins/pharmacology , Ileum , Intestinal Absorption , Mannans/pharmacology , Pepsin A/pharmacology , Plant Gums , Polymerase Chain Reaction/methods , Transgenes/drug effectsABSTRACT
The objective of this study was to determine whether recombinant plasmid DNA injected intramuscularly into chickens expressed the gene of interest in vivo and could be subsequently detected in primary and secondary lymphoid tissues with polymerase chain reaction (PCR). The VP2 capsid protein gene of the standard challenge strain (STC) of infectious bursal disease virus (IBDV) was cloned into a eukaryotic plasmid, and purified DNA was prepared. Fourteen 2-wk-old chickens were injected in the pectoral musculature with 500 microg of plasmid DNA dissolved in sterile PBS. Seven chickens were similarly injected with PBS alone. Pectoral muscle, thymus, spleen, bursa of Fabricius, and cecal tonsils were collected at 12, 24, 36, 48, 72, 96, and 168 h postinjection for detection of protein expression (in muscle) and to extract total DNA for PCR amplification of the VP2 capsid gene. Expression of VP2 was demonstrated in muscle tissue at 12 and 24 h postinjection by using an indirect immunofluorescence assay. PCR amplification with primers specific for the VP2 gene showed that the DNA was present in the thymus, spleen, and bursa of Fabricius but not in cecal tonsils. These results demonstrate that plasmid DNA injected directly into the pectoral muscle of chickens is transcribed and translated at the injection site and promptly distributed to primary and secondary lymphoid tissues.
Subject(s)
Chickens/metabolism , DNA, Recombinant/administration & dosage , Muscle, Skeletal/metabolism , Plasmids/genetics , Viral Structural Proteins/genetics , Animals , Bursa of Fabricius/metabolism , DNA, Recombinant/metabolism , DNA, Recombinant/pharmacokinetics , DNA, Viral/genetics , Gene Expression , Infectious bursal disease virus/genetics , Injections, Intramuscular , Molecular Sequence Data , Palatine Tonsil/metabolism , Polymerase Chain Reaction , Spleen/metabolism , Thymus Gland/metabolismABSTRACT
Effective gene therapy for diseases of the circulation requires vectors capable of systemic delivery. The molecular weight of poly(L-lysine) (pLL) has a significant effect on the circulation of pLL/DNA complexes in mice, with pLL(211)/DNA complexes displaying up to 20 times greater levels in the blood after 30 minutes compared with pLL(20)/DNA. It is shown that pLL(20)/DNA complexes fix mouse complement C3 in vitro, independent of immunoglobulin binding; are less soluble in the blood in vivo; bind erythrocytes; are rapidly removed by the liver, where they associate predominantly with Kupffer cells; and result in a rapid increase in hepatic leukocytes expressing high levels of complement receptor 3 (CR3). The circulation properties of these complexes are also dependent on the type of DNA used, with circular plasmid DNA complexes exhibiting increased circulation compared with linear DNA. PLL(211)/DNA complexes bind erythrocytes and associate with Kupffer cells but, in contrast, do not fix mouse complement in vitro and are unaffected by the type of DNA used. In rats, both types of complexes produce hematuria and are rapidly removed from the circulation. Correlation of in vivo and in vitro results suggests that the solubility of complexes in physiological saline and species-matched complement fixation and erythrocyte lysis may correlate with systemic circulation. Analysis using human blood in vitro shows no hemolysis, but both types of complexes fix complement and bind IgG, suggesting that pLL/DNA complexes may be rapidly cleared from the human circulation.
Subject(s)
DNA, Circular/pharmacokinetics , DNA, Recombinant/pharmacokinetics , Genetic Therapy , Genetic Vectors/pharmacokinetics , Polylysine/pharmacokinetics , Animals , Blood Proteins/metabolism , Complement Activation , Complement C3/metabolism , DNA, Circular/blood , DNA, Recombinant/blood , Female , Genetic Vectors/blood , Genetic Vectors/toxicity , Hematuria/chemically induced , Humans , Immunomagnetic Separation , Injections, Intravenous , Kupffer Cells/metabolism , Leukocytes/metabolism , Liver/metabolism , Mice , Mice, Inbred BALB C , Molecular Weight , Polylysine/blood , Polylysine/chemistry , Polylysine/toxicity , Rats , Rats, Wistar , Receptors, Complement/biosynthesis , Solubility , Species Specificity , Tissue Distribution , TransfectionABSTRACT
In radioimmunoguided surgery (RIGS), a radiolabeled antibody is given i.v. before surgery and a hand-held gamma-detecting probe is used to locate tumor in the operative field. The rapid blood clearance and good tumor penetration of single-chain Fv antibodies (scFv) offer potential advantages over larger antibody molecules used previously for RIGS. A Phase I clinical trial is reported on RIGS with scFv (MFE-23-his) to carcinoembryonic antigen (CEA). Thirty-four patients undergoing surgery for colorectal carcinoma (17 primary tumors, 16 liver metastases, and 1 anastomotic recurrence) and 1 patient with liver metastases of pancreatic carcinoma received 125I-labeled MFE-23-his scFv (125I-MFE-23-his) 24, 48, 72, or 96 h before operation. 125I-MFE-23-his showed biexponential blood clearance with alpha and beta half-lives of 0.32 and 10.95 h, respectively. The abdomen was scanned during surgery with a hand-held gamma detecting probe (Neoprobe Corp.). 125I-MFE-23-his showed good tumor localization; comparison with histology showed overall accuracy of 84%. Highest median ratios for tumor:normal tissue and tumor:blood were recorded 72 or 96 h after scFv injection for patients undergoing resection of liver metastases. High levels of radioactivity were found in the kidneys. Five patients had grade 1 fever, and three had a grade 1 rise in blood pressure according to the Common Toxicity Criteria. There was a significant correlation between these ratios and those measured in excised tissues using a laboratory gamma counter (P < 0.001). MFE-23-his scFv antibody localizes in CEA-producing carcinomas. The short interval between injection and operation, the lack of significant toxicity, and the relatively simple production in bacteria make MFE-23-his scFv suitable for RIGS.
Subject(s)
Antibodies/therapeutic use , Carcinoembryonic Antigen/immunology , Colorectal Neoplasms/surgery , Immunoglobulin Fragments/therapeutic use , Radioimmunodetection/methods , Adult , Aged , Aged, 80 and over , Antibodies/genetics , Colon/drug effects , Colon/metabolism , Colon/pathology , Colorectal Neoplasms/diagnostic imaging , Colorectal Neoplasms/pathology , DNA, Recombinant/pharmacokinetics , DNA, Recombinant/therapeutic use , Female , Genetic Engineering , Humans , Immunoglobulin Fragments/genetics , Iodine Radioisotopes/pharmacokinetics , Liver Neoplasms/diagnostic imaging , Liver Neoplasms/secondary , Lymph Nodes/metabolism , Lymph Nodes/pathology , Lymphatic Metastasis , Male , Middle Aged , Tissue DistributionABSTRACT
Easy accessibility makes the skin extremely attractive for therapeutic gene transfer, but this feature may be equally responsible for inadvertent DNA uptake. Therefore we studied lacZ reporter gene expression after epicutaneous and intracutaneous administration of naked DNA, lipofection and transferrinfection to intact, tape-stripped, and wound-healing skin of hairless mice. Gold particles coated with 1 microg pCMVnlslacZ were inoculated with a gene gun as a positive control. Beta-galactosidase expression by skin cells, i.e., keratinocytes of the upper epithelial layers and single cells in the upper dermis, determined by X-Gal histochemistry was not observed except after ballistic gene transfer. By polymerase chain reaction we detected lacZ DNA after skin bombardment up to 4 weeks. After intracutaneous and epicutaneous application to normal and tape-stripped skin of the various delivery systems lacZ DNA was detectable up to 1 week. Epicutaneous application of the delivery systems to wounded skin resulted in lacZ DNA detectability up to 48 h only. Reverse-transcriptase polymerase chain reaction indicated transcription of the reporter gene after particle bombardment and intracutaneous injection, up to 48 h, but not after epicutaneous application of either delivery system. The possibility of inadvertent uptake of exogeneous DNA by intact and tape-stripped skin is evidenced by the detection of reporter gene DNA after epicutaneous application of naked DNA and DNA complexed to cationic lipids or transferrin-polylysine (transferrinfection). However, the effects of the presence and persistence of foreign genes in the target cells are not clear yet.
Subject(s)
DNA, Recombinant/pharmacokinetics , Skin/metabolism , Administration, Cutaneous , Animals , Biolistics , Cation Exchange Resins , DNA, Recombinant/administration & dosage , Epidermis/injuries , Epidermis/metabolism , Gene Expression Regulation , Genes, Reporter , Genetic Therapy/methods , Keratinocytes/metabolism , Lac Operon , Lipids , Liposomes , Male , Mice , Mice, Hairless , Polylysine/analogs & derivatives , RNA, Messenger/biosynthesis , Recombinant Fusion Proteins/biosynthesis , Recombinant Fusion Proteins/genetics , Reverse Transcriptase Polymerase Chain Reaction , Skin/injuries , Transferrin/analogs & derivatives , beta-Galactosidase/biosynthesis , beta-Galactosidase/geneticsABSTRACT
The receptor-ligand interaction between hepatocyte heme receptors and heme was evaluated as a basis for developing a targeted cationic lipid delivery reagent for nucleic acids. Heme (ferric protoporphyrin IX) was conjugated to the aminolipid dioleoyl phosphatidylethanolamine (DOPE) and used to form cationic lipid particles with dioleoyl trimethylammonium propane (DOTAP). These lipids particles (DDH) protect oligoribonucleotides from degradation in human serum and increase oligoribonucleotide uptake into 2.2.15 human hepatoma cells (to a level of 50-60 ng oligo/10(4) cells) when compared with the same lipid particles (DD) prepared identically without heme. The DDH heme level that was optimal for oligoribonucleotide delivery was also optimal for maximum expression of plasmid-encoded luciferase. The enhancing effect of heme was evident only at net particle negative charge. Fluorescence microscopy showed that DDH delivered oligoribonucleotides into both the 2.2.15 cell cytoplasm and nucleus. DDH may thus be a potentially useful delivery vehicle for oligonucleotide-based therapeutics and transgenes, appropriate for use in such liver diseases as viral hepatitis, hepatoma, and hypercholesterolemia.
Subject(s)
Carcinoma, Hepatocellular/pathology , Fatty Acids, Monounsaturated/administration & dosage , Heme/administration & dosage , Liver Neoplasms/pathology , Neoplasm Proteins/metabolism , Oligoribonucleotides/administration & dosage , Phosphatidylethanolamines/administration & dosage , Quaternary Ammonium Compounds/administration & dosage , Receptors, Cell Surface/metabolism , Animals , Cations , Cell Line , Cell Nucleus/metabolism , Chlorocebus aethiops , Cytoplasm/metabolism , DNA, Recombinant/administration & dosage , DNA, Recombinant/pharmacokinetics , Drug Carriers , Fatty Acids, Monounsaturated/chemistry , Fatty Acids, Monounsaturated/pharmacokinetics , Genes, Reporter , Genetic Vectors/administration & dosage , Genetic Vectors/pharmacokinetics , Heme/chemistry , Heme/pharmacokinetics , Humans , Kidney , Luciferases/biosynthesis , Luciferases/genetics , Mice , Microscopy, Fluorescence , Oligoribonucleotides/chemistry , Oligoribonucleotides/pharmacokinetics , Organ Specificity , Particle Size , Phosphatidylethanolamines/chemistry , Phosphatidylethanolamines/pharmacokinetics , Quaternary Ammonium Compounds/chemistry , Quaternary Ammonium Compounds/pharmacokinetics , Recombinant Fusion Proteins/biosynthesis , Recombinant Fusion Proteins/genetics , Species Specificity , Tumor Cells, Cultured , Vero CellsABSTRACT
Transgenic fish, owing to a number of advantages which they offer over other species, are proving to be valuable model systems for the study of gene regulation and development genetics in addition to being useful targets for the genetic manipulation of commercially important traits. Despite having begun only a decade ago, the production of transgenic fish has become commonplace in a number of laboratories world-wide and considerable progress has been made. In this review, we initially consider the various regulatory elements and coding genes which have been used in fish, and subsequently discuss and compare both the transient and long-term fate and expression patterns of injected DNA sequences in the context of the different factors which are likely to have an effect on the expression of transgenes.